Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluvoxamine for Early Treatment of Covid-19
NCT04668950Phase 3Completed
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of fluvoxamine in coronavirus disease 2019 (COVID-19), sponsored by Washington University School of Medicine. Started Dec 2020; status: completed.
02
Drugs
fluvoxamine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04668950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04668950.